Bromopride
Based on 3 publication(s) in Google Scholar
Bromopride is a selective, irreversible, competitive, and orally effective dopamine D2 receptor antagonist. Bromopride can pass through the blood-brain barrier, inhibit the vomiting center, and enhance gastrointestinal motility, exerting antiemetic and gastrointestinal motility effects. Bromopride antagonizes dopamine-mediated vomiting reflexes and promotes gastrointestinal smooth muscle contraction, and has no adverse effects on abdominal wall healing in rats with postoperative abdominal infection. Bromopride can be used for the study of digestive system diseases (such as gastric hypomotility, nausea and vomiting).
Para uso exclusivo en investigación. No vendemos a pacientes.
- Pureza: 99.53%
- No. CAS: 4093-35-0
- Fòrmula: C14H22BrN3O2
- Peso molecular:344.25
-
Almacenamiento:
4°C, sealed storage, away from moisture and light
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Actividad biológica
-
Chemical Information
-
Solvente y solubilidad
- Pureza y Documentación
- Referencias
-
Help & FAQs
-
GPCR/G Protein Compound Library
HY-L006
-
Neuronal Signaling Compound Library
HY-L013
-
FDA-Approved Drug Library
HY-L022
-
Drug Repurposing Compound Library
HY-L035
-
Neurotransmitter Receptor Compound Library
HY-L062
-
FDA Approved & Pharmacopeial Drug Library
HY-L066
-
Neurodegenerative Disease-related Compound Library
HY-L086
-
Off-patent Drug Library
HY-L141
-
Membrane Protein-targeted Compound Library
HY-L149
-
Membrane Receptor-targeted Compound Library
HY-L150
-
Highly Selective Inhibitors Library
HY-L158
-
Dopamine Receptor Compound Library
HY-L165
-
Bioactive Compound Library Max
HY-L181
-
MCE Bioactive Compound Library
HY-L001V
-
Drug Repurposing Compound Library Plus
HY-L035P
-
FDA-Approved Drug Library Plus
HY-L022P
-
FDA-Approved Drug Library Mini
HY-L022M
-
Bioactive Compound Library
HY-L001
-
High-Throughput Bioactive Compound Library
HY-L205
-
Lactylation Compound Library
HY-L249
Publications Citing Use of MedChemExpress (MCE) Bromopride
MoreVer todos los productos específicos de isoformas Dopamine Receptor
More
Actividad biológica
|
D2 Receptor |
Axon regeneration assay: Bromopride (100 μM; 5 d) significantly promotes axon regeneration in a rat cortical neuron scratch injury model and reversed the inhibitory effect of chondroitin sulfate proteoglycan (CSPG) on axon growth[1].
Metabolite analysis assay: Bromopride (10 μM; 4 h) can be metabolized into 20 metabolites in mouse, rat, rabbit, dog, monkey and human hepatocytes[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:Rat embryonic cortical neurons (21 DIV), mouse dorsal root ganglion (DRG) neurons
-
Concentration:100 μM (cortical scrape assay); unspecified (DRG assay, inferred from context)
-
Incubation Time:5 days (cortical scrape); 24 hours (DRG)
-
Result:Increased axon regeneration into the lesion area by ~1.6-fold compared to CSPG-treated controls in rat cortical cultures wounded at 21 DIV, as quantified by βIII-tubulin immunostaining and image analysis.
Enhanced total axon length per neuron in adult mouse DRG neurons cultured on CSPG-coated plates, demonstrating its ability to counteract CSPG-mediated growth inhibition.
Rat peritonitis model: Bromopride (1 mg/kg; subcutaneous injection; every 12 hours; 3/7 days) significantly reduced abdominal wall wound edema and fibrin deposition in Wistar rats with induced peritonitis 7 days after surgery, without affecting wound breaking strength[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Male Wistar rats (90-120 days, 350-575 g) with induced peritoneal sepsis via cecal ligation/perforation + left colon resection/anastomosis[3]
-
Dosage:1 mg/kg
-
Administration:Subcutaneous injection every 12 h until euthanasia (postoperative day 3 or 7)
-
Result:Rreduced abdominal wall edema (p=0.041) and fibrin deposition (p=0.041) compared to controls (GC7) on day 7, with no significant difference in wound breaking strength. No adverse effects on survival or clinical signs (apathy, diarrhea) were observed.
Chemical Information
-
No. CAS 4093-35-0
-
Appearance Solid
-
Peso molecular 344.25
-
Fòrmula C14H22BrN3O2
-
Color Off-white to light yellow
-
SMILES
O=C(NCCN(CC)CC)C1=CC(Br)=C(N)C=C1OC
-
Envío
Room temperature in continental US; may vary elsewhere.
-
Almacenamiento
4°C, sealed storage, away from moisture and light
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)
Publications (3)
-
Journal Impact Factor
-
Most Recent
-
Anal Chem
Exposome-Scale Investigation of Cl-/Br-Containing Chemicals Using High-Resolution Mass Spectrometry, Multistage Machine Learning, and Cloud Computing. [Abstract]2025 Jun 3;97(21):11099-11109. PMID: 40401576 -
Naunyn Schmiedebergs Arch Pharmacol
2025 Mar 17. PMID: 40095050 -
bioRxiv
A drug repurposing screen reveals dopamine signaling as a candidate therapeutic pathway for PIGA-CDG. [Abstract]2026 Apr 18:2026.04.17.719256. PMID: 42039650
Solvente y solubilidad
DMSO : 170 mg/mL (493.83 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Pureza y Documentación
-
Ficha de datos (277 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
-
Instrucciones de manejo (2659 KB)
Referencias
[1]. Huebner EA, et al. Diltiazem Promotes Regenerative Axon Growth. Mol Neurobiol. 2019 Jun;56(6):3948-3957. [Content Brief]
[2]. Dunne CE, et al. Metabolism of bromopride in mouse, rat, rabbit, dog, monkey, and human hepatocytes. Drug Metab Pharmacokinet. 2013;28(6):453-61. [Content Brief]
[3]. Oliveira MV, et al. Effects of bromopride on abdominal wall healing with induced peritoneal sepsis after segmental colectomy and colonic anastomosis in rats. Acta Cir Bras. 2011 Dec;26(6):433-7. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.9049 mL | 14.5243 mL | 29.0487 mL | 72.6216 mL |
| 5 mM | 0.5810 mL | 2.9049 mL | 5.8097 mL | 14.5243 mL | |
| 10 mM | 0.2905 mL | 1.4524 mL | 2.9049 mL | 7.2622 mL | |
| 15 mM | 0.1937 mL | 0.9683 mL | 1.9366 mL | 4.8414 mL | |
| 20 mM | 0.1452 mL | 0.7262 mL | 1.4524 mL | 3.6311 mL | |
| 25 mM | 0.1162 mL | 0.5810 mL | 1.1619 mL | 2.9049 mL | |
| 30 mM | 0.0968 mL | 0.4841 mL | 0.9683 mL | 2.4207 mL | |
| 40 mM | 0.0726 mL | 0.3631 mL | 0.7262 mL | 1.8155 mL | |
| 50 mM | 0.0581 mL | 0.2905 mL | 0.5810 mL | 1.4524 mL | |
| 60 mM | 0.0484 mL | 0.2421 mL | 0.4841 mL | 1.2104 mL | |
| 80 mM | 0.0363 mL | 0.1816 mL | 0.3631 mL | 0.9078 mL | |
| 100 mM | 0.0290 mL | 0.1452 mL | 0.2905 mL | 0.7262 mL |
Bromopride Related Classifications
HY-B1164 Related Classifications
Powered by Bioz